• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

中枢神经系统穿透能力：治疗 SARS-CoV-2 脑感染药物的关键因素。

CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.

机构信息

Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Cottingham Road, HU6 7RX Hull, United Kingdom.

出版信息

ACS Chem Neurosci. 2020 Aug 5;11(15):2137-2144. doi: 10.1021/acschemneuro.0c00335. Epub 2020 Jul 8.

DOI:10.1021/acschemneuro.0c00335
PMID:32639711
Abstract

Now, it has been evidenced that Covid19 (SARS-CoV-2) infects the brain tissues. Along with this, a challenge has been raised for research professionals to find effective drugs for its treatment since the recent spread of this virus from Wuhan, China. Targeting the treatment of brain infection, it has also been a challenge that the clinical drug should have good CNS penetration ability to cross the blood-brain barrier.

摘要

现在，已经有证据表明新冠病毒（SARS-CoV-2）感染脑组织。随着新冠病毒从中国武汉的传播，研究人员面临着寻找有效药物治疗这种病毒的挑战。针对脑部感染的治疗，临床药物还需要具有良好的中枢神经系统穿透能力以穿透血脑屏障，这也是一个挑战。

相似文献

1
CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.中枢神经系统穿透能力：治疗 SARS-CoV-2 脑感染药物的关键因素。
ACS Chem Neurosci. 2020 Aug 5;11(15):2137-2144. doi: 10.1021/acschemneuro.0c00335. Epub 2020 Jul 8.
2
CNS penetration of potential anti-COVID-19 drugs.潜在抗新冠病毒药物的中枢神经系统穿透性。
J Neurol. 2020 Jul;267(7):1880-1882. doi: 10.1007/s00415-020-09866-5. Epub 2020 May 2.
3
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.评估静脉用瑞德西韦治疗成人重症 COVID-19 的疗效和安全性：一项 3 期随机、双盲、安慰剂对照、多中心试验的研究方案。
Trials. 2020 May 24;21(1):422. doi: 10.1186/s13063-020-04352-9.
4
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.支持瑞德西韦治疗新型冠状病毒感染的论据。
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
5
Audio Interview: New Data on Remdesivir in Covid-19.音频访谈：瑞德西韦治疗新冠病毒病的新数据
N Engl J Med. 2020 May 28;382(22):e94. doi: 10.1056/NEJMe2019975.
6
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.用于 SARS-CoV-2 治疗的潜在抗病毒药物：临床前发现和正在进行的临床研究。
In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949.
7
Liver injury in remdesivir-treated COVID-19 patients.接受瑞德西韦治疗的新冠肺炎患者的肝损伤
Hepatol Int. 2020 Sep;14(5):881-883. doi: 10.1007/s12072-020-10077-3. Epub 2020 Jul 28.
8
Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.瑞德西韦治疗 COVID-19 的可能分子机制：需要了解更多。
Arch Med Res. 2020 Aug;51(6):585-586. doi: 10.1016/j.arcmed.2020.05.001. Epub 2020 May 12.
9
[Remdesivir, the antiviral hope against SARS-CoV-2].[瑞德西韦，对抗新型冠状病毒的抗病毒希望]
Rev Esp Quimioter. 2020 Jun;33(3):176-179. doi: 10.37201/req/028.2020. Epub 2020 Apr 1.
10
Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.瑞德西韦治疗 COVID-19 的文献系统评价。
West J Emerg Med. 2020 May 20;21(4):737-741. doi: 10.5811/westjem.2020.5.47658.

引用本文的文献

1
CNS-Active p38α MAPK Inhibitors for the Management of Neuroinflammatory Diseases: Medicinal Chemical Properties and Therapeutic Capabilities.CNS 活性 p38α MAPK 抑制剂用于神经炎症性疾病的治疗：药物化学性质和治疗能力。
Mol Neurobiol. 2024 Jul;61(7):3911-3933. doi: 10.1007/s12035-023-03829-3. Epub 2023 Dec 2.
2
Oxidative stress and COVID-19-associated neuronal dysfunction: mechanisms and therapeutic implications.氧化应激与 COVID-19 相关神经元功能障碍：机制与治疗意义。
Acta Biochim Biophys Sin (Shanghai). 2023 Jun 25;55(8):1153-1167. doi: 10.3724/abbs.2023085.
3
COVID-19-induced neurological symptoms: focus on the role of metal ions.
COVID-19 引发的神经系统症状：关注金属离子的作用。
Inflammopharmacology. 2023 Apr;31(2):611-631. doi: 10.1007/s10787-023-01176-2. Epub 2023 Mar 9.
4
Effect of Toll-Like Receptor 7 Gene Polymorphism and ABO Blood Groups on the Severity of COVID-19 Patients.Toll样受体7基因多态性和ABO血型对COVID-19患者病情严重程度的影响
Acta Inform Med. 2022 Sep;30(3):191-195. doi: 10.5455/aim.2022.30.191-195.
5
Favipiravir and Its Structural Analogs: Antiviral Activity and Synthesis Methods.法匹拉韦及其结构类似物：抗病毒活性与合成方法。
Acta Naturae. 2022 Apr-Jun;14(2):16-38. doi: 10.32607/actanaturae.11652.
6
Mechanistic Understanding from Molecular Dynamics in Pharmaceutical Research 2: Lipid Membrane in Drug Design.药物研究中分子动力学的机理理解2：药物设计中的脂质膜
Pharmaceuticals (Basel). 2021 Oct 19;14(10):1062. doi: 10.3390/ph14101062.
7
COVID-19 and Alzheimer's disease: how one crisis worsens the other.COVID-19 与阿尔茨海默病：一场危机如何加重另一场危机。
Transl Neurodegener. 2021 Apr 30;10(1):15. doi: 10.1186/s40035-021-00237-2.
8
Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.通过评估其对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抑制活性来鉴定用于治疗2019冠状病毒病（COVID-19）的多效药物。
Comput Struct Biotechnol J. 2021;19:1998-2017. doi: 10.1016/j.csbj.2021.04.014. Epub 2021 Apr 7.
9
Roles of Microglial Ion Channel in Neurodegenerative Diseases.小胶质细胞离子通道在神经退行性疾病中的作用
J Clin Med. 2021 Mar 17;10(6):1239. doi: 10.3390/jcm10061239.
10
Modeling SARS-CoV-2 infection in individuals with opioid use disorder with brain organoids.利用脑类器官对患有阿片类药物使用障碍的个体的新型冠状病毒2型感染进行建模。
J Tissue Eng. 2021 Feb 26;12:2041731420985299. doi: 10.1177/2041731420985299. eCollection 2021 Jan-Dec.